All In Biotech

NDA 021134 · Viatris

Nitrostat

Nitroglycerin · Sublingual · Nitrate Vasodilator

Last checked: Nov 20, 2026Latest source record: Jan 24, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

May 1, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

237

47 Phase 3, 10 recruiting

FAERS reports

50,659

39,953 serious, 6,683 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2026.

NITROSTAT is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. INDICATIONS AND USAGE NITROSTAT is a nitrate vasodilator indicated for relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • NITROSTAT · NITROGLYCERIN 0.6MG · TABLET, SUBLINGUAL · Prescription · TE AB
  • NITROSTAT · NITROGLYCERIN 0.3MG · TABLET, SUBLINGUAL · Prescription · TE AB
  • NITROSTAT · NITROGLYCERIN 0.4MG · TABLET, SUBLINGUAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitroglycerin" as an intervention, any sponsor and status, largest first.

All 237 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea4,097
  • pain3,585
  • fatigue3,446
  • myocardial infarction3,238
  • nausea3,200
  • drug ineffective2,960
  • dizziness2,873
  • chest pain2,869
  • fall2,869
  • diarrhoea2,649
  • headache2,556
  • renal failure2,467

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,000
20051,168
2006999
2007738
2008946
20091,304
20101,528
20112,468
20122,114
20131,251
20143,042
20152,372
20162,914
20172,764
20183,081
20193,145
20202,768
20212,666
20223,197
20233,162
20243,072
20252,988
20261,968

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nitrostat (Nitroglycerin)

2024 spending

$175K

Beneficiaries

2,227

3,269 claims

Per beneficiary

$79

$1.17 per unit

View as table
YearSpending
2020$506,688
2021$377,673
2022$270,472
2023$240,025
2024$175,500

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,057 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.